Partners Innovation Fund & Company Creation


Partners Innovation Fund

The Partners Innovation Fund was created in 2008 to advance new science and technology based on Partners' intellectual and financial capital. From the initial commitment of $35M from BWH and MGH, the fund has grown to $171 million through internal and external investment.

PIF invests exclusively in healthcare companies based on intellectual property created within our own research community.  We seek strong co-investor syndicates to build companies focused on drugs, devices, diagnostics and digital health.

Our mission at Partners Innovation Fund (“PIF”) is to create ventures that develop new drugs and technologies based on inventions originating from Partners. Click here to learn more: Partners Innovation Fund

View our PIF Portfolio

In the News

Keros Therapeutics Receives a $23 million Series B funding

January 7, 2019

Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases, announced a $23 million Series B financing today. This investment, coupled with Series A in 2016, brings the company’s total venture funding to $34 million to date. The financing round included participation from existing investors Pontifax, Arkin Bio Ventures, Partners Innovation…

Alexion To Acquire Syntimmune

September 26, 2018

BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune today announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). SYNT001 – a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes –…

U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

September 20, 2018

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy…


August 7, 2018

Boston, Mass. – August 7, 2018 – Akouos, a precision genetic medicine company developing gene therapies that restore and preserve hearing, today announced the Company has raised $50 million in Series A financing. Seed investors 5AM Ventures and New Enterprise Associates (NEA) co-led the round, and were joined by existing seed investor Partners Innovation Fund and new…

Translate Bio Announces Pricing of Initial Public Offering

August 3, 2018

Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross…

Lyndra Inc. and Global Drug Commercialization Center Announce Joint Venture to Develop Lyndra’s Ultra-long-acting Oral Dosage Form for Chinese Market

May 8, 2018

Lyndra Inc., an emerging biopharmaceutical company, today announced the formation of a joint venture with Global Drug Commercialization Center (GDCC) to commercialize Lyndra’s groundbreaking medicines in China. The partners held a public ribbon-cutting ceremony for the new Lyndra (China) Pharmaceuticals Co., Ltd. headquarters in Chengdu, China. Lyndra is developing ultra-long-acting oral therapies that free patients…

Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

April 6, 2018

Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced treatment of the first patient with an inherited metabolic disorder in a Phase 2 study of MGTA-456.

Denali Therapeutics prices IPO at $18 midpoint making it the largest biotech IPO of the year

December 8, 2017

Denali Therapeutics, a an early-stage biotech developing novel therapies for neurodegenerative diseases, raised $250 million by offering 13.9 million shares at $18, within the range of $17 to $19. At pricing, the company commands a fully diluted market value of $1.7 billion.  

Partners HealthCare raises $171 million to invest in early-stage life science companies

November 8, 2017

Partners HealthCare System announced today the closing of $171.1 million in capital to invest in early-stage life sciences companies, which are a critical segment of the state’s innovation economy. The funds raised include $66.1 million in outside capital for Partners Innovation Fund II and a $105 million commitment from Partners institutions to Partners Innovation Fund. …

Spero Therapeutics Announces Closing of Initial Public Offering

November 7, 2017

Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions.  In addition, Spero Therapeutics, Inc. has granted the…

Spero Therapeutics Announces Pricing of Initial Public Offering

November 2, 2017

Two biotechs, Spero Therapeutics and Allena Therapeutics, are headed for the Nasdaq this morning at valuations they’d been aiming for. Their stock offerings are the latest sign of the health of the biotech IPO market, and the willingness of insiders to make sure these deals succeed. For more information, click here

Fierce Biotech Names Magenta Therapeutics as one of its “Fierce 15” Biotech Companies of 2017

September 27, 2017

Magenta Therapeutics, a biotechnology company developing therapeutics to improve and expand the use of curative hematopoietic stem cell transplantation for more patients, today announced that it has been named by FierceBiotech as one of the Fierce 15 biotechnology companies of 2017. This award designates Magenta Therapeutics as one of the most promising private biotechnology companies…

Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products

September 8, 2017

Lyndra, Inc. (Lyndra) announced today a partnership with Allergan plc to develop orally administered ultra-long-acting (once-weekly) products for the treatment of Alzheimer’s disease. The basis of the collaboration between the Boston-based startup and Allergan is Lyndra’s innovative sustained-release technology, which has the potential to transform drugs typically dosed daily to once-weekly oral dosing.

RaNA Therapeutics Relaunches as Translate Bio

June 27, 2017

RaNA Therapeutics today announced the company has relaunched as Translate Bio. Translate Bio is a leading biotechnology company pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases.

Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners

June 21, 2017

Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with additional participation from other existing investors. The funds from the Series B financing will further advance Syntimmune’s clinical development program.

PHS Spin-off to develop cancer-fighting antibody

May 22, 2017

Fierce Biotech details how MS research at the BWH created an opportunity for PHS spin-off, Tilos, to develop a cancer-fighting antibody.

Partners HealthCare International (PHI) to merge with Partners Innovation

October 13, 2016

On October 1, Partners HealthCare International® (PHI) joined with Partners Innovation. This merger unites a team of more than 110 working to deliver the unique strengths of Partners HealthCare and its faculty to the global markets. PHI was founded in the 1990’s as an arm of Harvard Medical School under the name Harvard Medical International.…

Partners HealthCare and Health Catalyst Honored as Recipients of the 2016 Microsoft Health Innovation Awards

March 9, 2016

SALT LAKE CITY and BOSTON, March 3, 2016 /PRNewswire/ — Health Catalyst and Partners HealthCare today announced they have been named recipients of Microsoft Corp.’s 2016 Health Innovation Awards. The organizations won the “Reinventing Productivity and Business Processes” category, which evaluates solutions that transform care delivery or population health by connecting clinicians and staff to…

Health Catalyst Announces New Products at HIMSS16

March 1, 2016

From the floor of the HIMSS16 Conference and Exhibition in Las Vegas, Health Catalyst announced it is launching the most significant update to its technology and product strategy since the introduction of its industry-changing Late-Binding™ Enterprise Data Warehouse (EDW) in 2008. The expansion of Health Catalyst’s product development program comes with the strong endorsement of…

QPID Acquired by Leading Technology-Enabled Medical Benefit Management Company eviCore healthcare

February 29, 2016

Leading Technology-Enabled Medical Benefit Management Company eviCore healthcare Acquires QPID Health Combined entity will support healthcare’s shift to value-based care with advanced analytics, software and services to support payers, hospitals, physicians and patients BLUFFTON, SC – February 29, 2016 – eviCore healthcare, a company committed to enabling better outcomes for patients, payers and providers through…

Editas Medicine pricing shares at $16 for year’s first IPO: reports

February 3, 2016

Editas Medicine Inc. EDIT, +0.00% priced shares for its initial public offering at the low end of the range, according to media reports late Tuesday, for what will be 2016’s first IPO. Editas will price 5.9 million shares at $16 a share, at the low end of its $16 to $18 range, to raise $94.4…

Partners HealthCare puts millions toward in-house innovation

January 13, 2016

The state’s largest health care system is putting an increased focus on financing homegrown innovations, with Partners HealthCare putting another $65 million in a fund used to invest in Partners technologies while opening the door to outside investors. The Partners Innovation Fund, created in 2007 with $35 million from Partners, was intended to progress Partners-developed…

Partners Innovation Fund Grows to $100 Million

January 12, 2016

Nine years ago, a grand Partners HealthCare experiment was launched. Not on a laboratory bench or in an exam room but on an organization-wide scale. With $35 million at stake, the concept was to run a venture model from within Partners with ready capital and experienced internal venture investors who could steward the creation of…

Cambridge startup Editas plans to test IPO market for biotechs

January 8, 2016

Editas Medicine Inc., a Cambridge startup that is developing treatments to modify disease-causing genetic defects, plans to go public in a deal that could test the strength of the market for new biotech stocks. In a filing Monday with the Securities and Exchange Commission, two-year-old Editas did not specify the sales price range or when…

FierceBiotech’s 2015 Fierce 15

January 8, 2016

Partners Innovation Fund portfolio company and PHS licensee Denali Therapeutics was selected for FierceBiotech’s 2015 highly competitive Fierce 15.

Roch picks up a new autoimmune drug with $580M Adheron deal

January 8, 2016

10-9 – BWH spinout and PIF portfolio company, Adheron, has been acquired by Roch. Adheron is developing antibodies (currently in Phase I) targeting cadherin-11 for treatment of rheumatoid arthritis and other indications, and is based on technology developed by Michael Brenner, MD at BWH. Roche will be a great partner to move the product forward…

Blue Cross Blue Shield invests in Newton medical imaging company lifeIMAGE

January 8, 2016

10-2- PHS spin-off and Partners Innovation Fund portfolio company, lifeIMAGE, announced a $5 million strategic investment from Zaffre Investments, LLC, the investment arm of Blue Cross Blue Shield of Massachusetts. This investment follows the $17.5 million round of financing lifeIMAGE received in May.

FierceBiotech’s 2015 Fierce 15

November 11, 2015

Whatever lies ahead for biotech in 2016, we can now look back on a 3-year-long stretch of good times for the industry. Venture groups have used the wave of biotech IPO exits and M&A deals to go back and raise more money from institutional investors. And as billions of dollars in fresh capital has converged…

Cambridge-based Editas gets $120M investment to advance genome editing

November 11, 2015

Kendall Square startup Editas Medicine, which aims to cure diseases by fixing disease-causing genes, today announced a $120 million investment, representing the second-largest venture capital rounds in Massachusetts so far this year. The Series B round comes from more than a dozen public and private investors, some of which — like New York City-based Deerfield…

GeneInsight wins Bio-IT World’s Best Practice Award

April 10, 2013

Boston—Bio-IT World announced the winners of its ninth Best Practices Awards competition this morning in a plenary session at the 2013 Bio-IT World Conference & Expo in Boston. Grand prize winners were named in four life sciences categories highlighting best practices in genomics, cloud computing, big data in disease research, and big pharma data management…

Partners Innovation Fund Team